well the simple truth is - it is difficult to sell and displace exisiting methods. Even if the products are sound and better, re-educating surgeons take years and years. And then there is the fact that the time period to see product effectiveness takes a good 18 - 24 months. So from early orders to seeing benefit to re-orders takes a good 2 - 3 years.
More staff means more cash burn, they need to manage with exisiting strength for now. Different conversation once they reach break even.
I like many here am frustrated too, but this is the reality of the challenging biotech sector.
Ann: Activities Update Qtr Ending September 2023 and Appendix 4C, page-5
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OSX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.2¢ |
Change
0.001(2.44%) |
Mkt cap ! $4.853M | |||
| Open | High | Low | Value | Volume |
| 4.2¢ | 4.2¢ | 4.1¢ | $28.26K | 677.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 1970764 | 4.1¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.2¢ | 101043 | 1 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| OSX (ASX) Chart |